Citations

Mayo Clinic

Showing 10 of 108572 citations.

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin, D’Angelo, Christopher R. , Elsedawy, Noura, Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo, Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Sborov, Douglas W. , Valent, Jason , Varshavsky‐Yanovsky, Asya, Snedeker, Jenna, Holmberg, Leona , Anderson, Larry D , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Castillo, Jorge J. , Costello, Caitlin , Devarakonda, Srinivas , Garfall, Alfred L. , Htut, Myo , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Kumar, Rashmi

Journal of the National Comprehensive Cancer Network | December 11, 2023 | Volume: 21 | Issue: 12 | Pages: 1281-1301

10.6004/jnccn.2023.0061 | PMID 38081133 Get It

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
The Effect of Adding Physician Recommendation in Digitally-Enabled Outreach for COVID-19 Vaccination in Socially/Economically Disadvantaged Populations Subtitle: A Randomized Controlled Trial
Sumar, Kamal, Blue, Lisa, Fatahi, Gina, Bhatti, Atiq ur Rehman , Sumar, Mehek, Alvarez, Stéphanie, Cons, Pedro, Valencia, Nathalie, Bhatti, Atiq

No container title available | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3604972/v1 | PMID 38168293 Get It

Abstract Introduction: People from backgrounds that are economically/socially disadvantaged experienced disproportionately high COVID-19 death rates and had lower vaccination rates. Effective outreach strategies for increasing vaccine uptake during the pandemic are not fully known. Among patients receiving care at a Federally Qualified Health Center, we tested whether community engaged digitally-enabled outreach increased COVID vaccine uptake. Study Design, Setting, and Participants: A 3-parallel-arm randomized controlled trial with a hybrid effectiveness-implementation design was conducted among patients ≥18 years old on study enrollment during 2021 with 1,650 assigned in 3:10:20 ratio; 2,328 were later selected for two subsequent implementation rounds. Interventions: From April 13 to June 10, 2021, patients were proactively sent a text-messaging invitation to make an appointment for vaccination as part of the routine practice (Arm 1, n=150) with added personalized clinician recommendation alone (Arm 2, n=500) or with an explicit nudge for answers to frequently asked questions (Arm 3, n=1,000). Further implementation used messaging addressing vaccine hesitancy (n=1,323) or adverse reactions to vaccines (n=1,005). Main Outcomes and Measures: The primary outcome was the completion of the first SARS-Cov-2 vaccine dose determined at 14, 30 and 90 days after outreach. Results: Of 1,650 patients in effectiveness Arms, 61% was female. Vaccination rates for Arms 1, 2, and 3, were 6% (n=9), 5.4% (n=27) and 3.3% (n=33) at 14 days, and 11.5% (n=17), 11.6% (n=58), and 8.5% (n=85) at 90 days, respectively, which were similar in pairwise comparisons. At 90 days, vaccination rates were similar across the two implementation rounds (3.9% vs. 3.6%) and were similar to the rate (3.3%) among patients who were not selected for intervention arms or implementation rounds (n=8,671). Conclusions: Digitally-enabled outreach that included SMS messaging outreach augmented with clinician recommendations did not improve COVID-19 vaccination rates. Trial Registration: This study is registered at ClinicalTrails.gov Identifier: NC-T04952376
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Arend, Rebecca C. , Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Gaillard, Stéphanie , Giuntoli, Robert , Glaser, Scott , Holmes, Jordan A. , Howitt, Brooke E. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Aggarwal, Shaili, Espinosa, Sara, Gaillard, Stéphanie , Crispens, Marta Ann , Lea, Jayanthi Sivasothy , Mutch, David G.

Journal of the National Comprehensive Cancer Network | December 11, 2023 | Volume: 21 | Issue: 12 | Pages: 1224-1233

10.6004/jnccn.2023.0062 | PMID 38081139 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment. The guidelines also include details on histopathologic classification of cervical cancer regarding diagnostic features, molecular profiles, and clinical outcomes. The treatment landscape of advanced cervical cancer is evolving constantly. These NCCN Guidelines Insights provide a summary of recent updates regarding the systemic therapy recommendations for recurrent or metastatic disease.
Towards a Lightweight Classifier to Detect Hypovolemic Shock
Pramanik, Leena , Felton, Christopher L. , Techentin, Robert W., Holmes, David R. , Joyner, Michael J. , Haider, Clifton R. , Joyner, Michael J , Felton, Christopher L , Curry, Timothy B. , Convertino, Víctor A.

2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/embc40787.2023.10340949 | PMID 38083358 Get It

Dynamic Visualization of Gyral and Sulcal Stereoelectroencephalographic Contacts in Humans
Rockhill, Alexander P. , Ince, Nuri F. , Adamek, Markus , Brunner, Peter , Hermes, Dora

2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/embc40787.2023.10340652 | PMID 38083418 Get It

Assessing ChatGPT for Text Summarization, Simplification and Extraction Tasks
Malik, Sheza , Roy, Mousumi , Islam, Meena Z, Rasheed, Umair, Bian, Jiang , Zheng, Kai , Zhang, Rui , Bian, Jiang , Tariq, Raseen , Roy, Mousumi

2023 IEEE 11th International Conference on Healthcare Informatics (ICHI) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 746-749

10.1109/ichi57859.2023.00136 Get It

Enforcing Explainable Deep Few-Shot Learning to Analyze Plain Knee Radiographs: Data from the Osteoarthritis Initiative
Littlefield, Nickolas , Moradi, Hamidreza , Amirian, Soheyla , Plate, Johannes F. , Kremers, Hilal Maradit , Tafti, Ahmad P

2023 IEEE 11th International Conference on Healthcare Informatics (ICHI) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 252-260

10.1109/ichi57859.2023.00042 Get It

Detecting Reddit Users with Depression Using a Hybrid Neural Network SBERT-CNN
Chen, Ziyi , Zong, Nansu , Yang, Ren , Fu, Sunyang , Liu, Hongfang , Huang, Ming

2023 IEEE 11th International Conference on Healthcare Informatics (ICHI) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 193-199

10.1109/ichi57859.2023.00035 Get It

Mitigating Fracture of the Acromion and Scapular Spine After Reverse Shoulder Arthroplasty
Buchanan, Timothy R. , Bindi, Victoria E. , Caban-Klepac, Ettienne , Hones, Keegan M. , Wright, Thomas W. , King, Joseph J. , Hao, Kévin A. , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Hones, Keegan M , Schoch, Bradley S.

JBJS Reviews | December 11, 2023 | Volume: 11 | Issue: 12 | Pages: No page available

10.2106/jbjs.rvw.23.00175 | PMID 38079495 Get It

» Biomechanical studies report that thin scapular spine (SS) morphology, superiorly placed glenoid components, and increased glenoid baseplate screws contribute to increased acromial and SS strain and may increase fracture risk. » Clinical risk factors of acromial and SS fractures after reverse shoulder arthroplasty include increasing age, female sex, osteoporosis, rheumatoid arthritis, thin midsubstance acromion morphology, previous acromioplasty, and surgical indication of cuff tear arthropathy. » Clinical studies show that, in isolation, excessive humeral lengthening, humeral lateralization, and glenoid medialization may increase risk of acromial and SS fractures. » Biomechanical studies suggest that a combination of glenoid medialization and humeral lateralization (MG/LH) may reduce fracture risk, although this requires clinical correlation. » Surgeons might reduce fracture risk in patients of high-risk groups by guarding against excessively lengthening the humerus, using a MG/LH prosthesis, and targeting screws to avoid the scapular notch and base of the SS. Level of Evidence: Level V . Narrative Review. See Instructions for Authors for a complete description of levels of evidence.
Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies
Zhu, Mojun , Then, Sara S., Berger, Calise K. , Burger, Kelli N. , Gonser, Anna M. , Doering, Karen A. , Xie, Hao , Foote, Patrick H. , Kaiser, Michael W., Allawi, Hatim T. , Berger, Calise K , Gonser, Anna M , Doering, Karen A , Xie, Hao , Foote, Patrick H , Taylor, William R. , Mahoney, Douglas W. , Hubbard, Joleen M. , Kisiel, John B.

Cancers | December 11, 2023 | Volume: 15 | Issue: 24 | Pages: 5778

10.3390/cancers15245778 | PMID 38136324 Get It

Background: Radiographic surveillance of colorectal cancer (CRC) after curative-intent therapy is costly and unreliable. Methylated DNA markers (MDMs) detected primary CRC and metastatic recurrence with high sensitivity and specificity in cross-sectional studies. This study evaluated using serial MDMs to detect recurrence and monitor the treatment response to anti-cancer therapies. Methods: A nested case-control study was drawn from a prospective cohort of patients with CRC who completed curative-intent therapy for CRC of all stages. Plasma MDMs were assayed vis target enrichment long-probe quantitative-amplified signal assays, normalized to B3GALT6, and analyzed in combination with serum carcinoembryonic antigen to yield an MDM score. Clinical information, including treatment and radiographic measurements of the tumor burden, were longitudinally collected. Results: Of the 35 patients, 18 had recurrence and 17 had no evidence of disease during the study period. The MDM score was positive in 16 out of 18 patients who recurred and only 2 of the 17 patients without recurrence. The MDM score detected recurrence in 12 patients preceding clinical or radiographic detection of recurrent CRC by a median of 106 days (range 90–232 days). Conclusions: Plasma MDMs can detect recurrent CRC prior to radiographic detection; this tumor-agnostic liquid biopsy approach may assist cancer surveillance and monitoring.